Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.

Trial Profile

Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2012

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2012 Additional lead trial investigator (Judith Wolf, MD) identified as reported by ClinicalTrials.gov.
    • 22 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top